What is the primary advantage of using a phage display immune antibody library for Canine (Dog) Monoclonal Antibody discovery over hybridoma?

Phage display allows for the screening of a much larger repertoire of antibodies (10^10 clones) compared to hybridoma. It enables the isolation of antibodies against toxic or non-immunogenic antigens and facilitates the direct cloning of variable regions for easy engineering.

What antibody formats can you produce?

We initially isolate binders as scFv or Fab fragments. These can be easily reformatted into full-length canine IgGs (subclasses A, B, C, or D) or other engineered formats (Bispecifics, CARs) upon request.

Is this service suitable for clinical diagnostic development?

While our antibodies are of high quality and affinity, this specific service is intended for research and discovery purposes. However, the antibodies discovered can be developed further into diagnostic or therapeutic tools by the client. Disclaimer: Our products are for research use only.

Can you screen for cross-reactivity with human targets?

Yes. During the Canine (Dog) Monoclonal Antibody Discovery process, we can introduce negative selection steps (subtraction panning) to remove binders that cross-react with human homologs, or conversely, select for those that do, depending on your project goals.

Advanced Canine (Dog) Monoclonal Antibody Discovery Service

Background Workflow Advantage Related Services FAQ Online Inquiry

At Creative Biolabs, we combine over 20 years of antibody engineering expertise with cutting-edge biotechnology to accelerate veterinary medicine. As a global leader in the field, we are proud to offer a comprehensive Canine (Dog) Monoclonal Antibody Discovery Service, specifically designed to generate high-affinity, high-specificity antibodies for research and therapeutic applications. Leveraging our advanced phage display immune antibody library platform, we overcome the limitations of traditional hybridoma technology, providing scientists and pharmaceutical developers with a robust solution for the construction and screening of immune antibody library tailored to the canine immune repertoire.

Discuss Your Project Today

The New Frontier: Phage Display-Based Canine (Dog) Monoclonal Antibody Discovery

The demand for species-specific biologics in veterinary medicine is growing exponentially. While "caninized" antibodies (murine antibodies engineered to look like dog antibodies) have been the standard, they often suffer from immunogenicity issues and lower affinity.

Our service utilizes Canine (Dog) Monoclonal Antibody Discovery by phage display immune antibody library, a state-of-the-art strategy that isolates "native" canine antibodies directly from immunized donors. This approach preserves the natural heavy and light chain pairings found in the dog's immune system, ensuring superior developability and safety profiles.

Fig. 1 Production of E134Bf from EMab-134. (OA Literature) Fig. 1 Production of E134Bf (core-fucose-deficient dog IgGB) from EMab-134 (mouse IgG1).¹

Why Choose an Immune Antibody Library?

Unlike naïve libraries, an immune antibody library for Canine (Dog) Monoclonal Antibody is constructed from B-cells of donors that have been actively immunized with your target antigen. This results in a library enriched with binders that have already undergone in vivo affinity maturation.

Higher Affinity: Binders typically exhibit K_D values in the nanomolar to picomolar range.
Specific Epitope Targeting: Immunization strategies can be tailored to focus the immune response on specific domains.
Reduced Immunogenicity: Directly isolating canine sequences minimizes the risk of anti-drug antibodies (ADAs) in clinical settings.

Service Workflow: Construction and Screening of Immune Antibody Library

Our streamlined process ensures the delivery of high-quality Canine (Dog) Monoclonal Antibody candidates.

Step 1: Host Immunization

We utilize a variety of immunogens (proteins, peptides, DNA, or cells) to immunize healthy donor dogs. Our proprietary adjuvants and immunization schedules are optimized to elicit a robust humoral response.

Step 2: Library Construction

We isolate Total RNA from peripheral blood mononuclear cells (PBMCs), spleen, or lymph nodes. Using specialized primer sets designed for the canine antibody repertoire, we amplify VH and VL genes and clone them into our phagemid vectors to create a high-diversity (>10¹⁰) immune antibody library.

Step 3: Biopanning & Screening

The phage display-based Canine (Dog) Monoclonal Antibody library undergoes multiple rounds of biopanning against the target antigen. We utilize high-stringency washing steps to select for the tightest binders.

Step 4: Characterization & Production

Positive clones are sequenced and converted into full-length canine IgG (e.g., IgG-A, IgG-B, IgG-C, IgG-D) for expression and further characterization (Affinity measurement, Epitope binning).

Technology Spotlight: M13 Phage Display Platform

Our platform is distinct because we do not rely on generic primer sets. We have developed a proprietary set of degenerate primers that cover the vast majority of the canine V-gene families, ensuring that the immune antibody library for Canine (Dog) Monoclonal Antibody captures the full diversity of the host's response.

Why Choose Creative Biolabs for Canine & Bovine Antibody Discovery?

While we are leaders in canine research, our expertise extends across the veterinary spectrum. Creative Biolabs is unique in its ability to handle complex species-specific discovery.

Feature	Creative Biolabs Advantage
Experience	20+ years in antibody engineering and phage display.
Species Expertise	Deep understanding of Canine, Bovine, Porcine, and Equine immune repertoires.
Platform	Proprietary vectors and ultra-high diversity libraries (>10¹⁰).
Success Rate	Proven track record with difficult targets (GPCRs, Ion Channels).
End-to-End	From immunization to stable cell line development and pilot production.

Explore Our Comprehensive Services

While our phage display immune antibody library platform is a powerful engine, we offer a comprehensive suite of discovery technologies to ensure we always use the right tool for the job. Our Monoclonal Antibody Generation from Various Immunized Antibody Libraries Services:

Ready to start your project? Contact our team today to discuss your specific requirements for Canine (Dog) Monoclonal Antibody Discovery. Let Creative Biolabs be your partner in advancing veterinary health.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: What is the primary advantage of using a phage display immune antibody library for Canine (Dog) Monoclonal Antibody discovery over hybridoma?
A: Phage display allows for the screening of a much larger repertoire of antibodies 10^10 clones compared to hybridoma. It enables the isolation of antibodies against toxic or non-immunogenic antigens and facilitates the direct cloning of variable regions for easy engineering.
Q: What antibody formats can you produce?
A: We initially isolate binders as scFv or Fab fragments. These can be easily reformatted into full-length canine IgGs (subclasses A, B, C, or D) or other engineered formats (Bispecifics, CARs) upon request.
Q: Is this service suitable for clinical diagnostic development?
A: While our antibodies are of high quality and affinity, this specific service is intended for research and discovery purposes. However, the antibodies discovered can be developed further into diagnostic or therapeutic tools by the client.

Disclaimer: Our products are for research use only.
Q: How long does the Construction and Screening of Immune Antibody Library take?
A: The typical timeline from immunization to the delivery of screened unique binders is approximately 4-5 months, depending on the immunogenicity of the target and the complexity of the screening required.
Q: Can you screen for cross-reactivity with human targets?
A: Yes. During the Canine (Dog) Monoclonal Antibody Discovery process, we can introduce negative selection steps (subtraction panning) to remove binders that cross-react with human homologs, or conversely, select for those that do, depending on your project goals.

Reference

Li, Guanjie, et al. "Defucosylated Mouse–Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors." Cells 10.12 (2021): 3599. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cells10123599

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.